CYTOO

CYTOO is a specialized biotech firm focused on revolutionizing muscle disease research and drug discovery through its proprietary MyoScreen™ platform. This integrated technology enables high-throughput, reproducible modeling of human muscle pathologies using patient-derived cells, serving pharmaceutical and biotech clients across target identification, validation, and lead profiling. The company's core value proposition lies in enhancing physiological relevance and standardization in preclinical models, thereby de-risking and accelerating the development of therapies for neuromuscular, genetic, and metabolic disorders. As a private, service and platform-based company, CYTOO collaborates with industry leaders to bridge a critical gap in functional muscle assays.

MyoScreen™ platform: An integrated discovery platform using proprietary micropatterning technology (CYTOOchips/CYTOOplates) to create standardized, physiologically relevant human muscle cell models from patient-derived primary myoblasts. Enables high-throughput, high-content screening for drug discovery and functional potency assay development.

CYTOO operates in a specialized niche within the broader preclinical CRO and cellular model market. Direct competitors may include other firms offering specialized muscle cell assays or micropatterning products, but CYTOO's integrated platform combining proprietary substrates, patient cells, and deep muscle biology expertise creates a distinct position. It also competes with academic core facilities and internal pharma labs seeking to build similar capabilities.